Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for SMA

Created at 4 Jun · 03:39 UTC2 sources↑ Market-relevant2 events

IN SHORT

The U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy (SMA). This designation aims to expedite the development and review of drugs for serious conditions, with preliminary evidence suggesting salanersen may offer substantial improvement over existing therapies for SMA with once-yearly dosing.

Key Numbers

June 04, 2026date of announcement

Who's Involved

Biogen Inc.

Announced FDA Breakthrough Therapy Designation for salanersen

U.S. Food and Drug Administration (FDA)

Granted Breakthrough Therapy Designation for salanersen

salanersen

Investigational drug for spinal muscular atrophy (SMA)

Key facts

Biogen's salanersen received FDA Breakthrough Therapy Designation for spinal muscular atrophy (SMA).
The designation expedites development and review for drugs treating serious conditions.
Preliminary clinical evidence suggests salanersen may substantially improve upon available SMA therapies.
Salanersen is an investigational antisense oligonucleotide (ASO) with potential for once-yearly dosing.

Biogen Inc. announced on June 04, 2026, that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy (SMA). This designation is designed to accelerate the development and review process for drugs intended to treat serious conditions. Preliminary clinical evidence indicates that salanersen, an investigational novel antisense oligonucleotide (ASO), may demonstrate substantial improvement over currently available therapies for SMA, with the potential for high efficacy and once-yearly dosing.

↳ Why This Matters

This designation could significantly speed up the availability of a potentially more effective treatment for spinal muscular atrophy, offering new hope to patients and their families and impacting the competitive landscape for SMA therapies.

FREQUENTLY ASKED

Breakthrough Therapy Designation is granted by the FDA to expedite the development and review of drugs for serious conditions, based on preliminary clinical evidence of substantial improvement over available therapies.

Salanersen is an investigational novel antisense oligonucleotide (ASO) developed by Biogen for the treatment of spinal muscular atrophy (SMA).

Spinal muscular atrophy (SMA) is a serious genetic condition that affects nerve cells in the spinal cord, leading to muscle weakness and atrophy.

Key facts

Biogen's salanersen received FDA Breakthrough Therapy Designation for spinal muscular atrophy (SMA).

The designation expedites development and review for drugs treating serious conditions.

Preliminary clinical evidence suggests salanersen may substantially improve upon available SMA therapies.

Salanersen is an investigational antisense oligonucleotide (ASO) with potential for once-yearly dosing.

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for SMA

PiQ Daily

Key facts

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for SMA

PiQ Daily

Key facts

Get the newsletter.